Cryopreservation for CAR-T cells should preserve more than a viable cell population. The practical question is whether thawed cells retain the recovery, CAR expression, and biological activity required by the next stage of the workflow. A strong result immediately after thawing is useful, but it does not describe how the cells perform later.
Selecting a CAR-T cryopreservation medium therefore requires a defined formulation, relevant cell-specific evidence, and evaluation under the intended process conditions. This guide explains how to assess those factors using CD19 CAR-T performance data for Kryogene™ Cell Freezing Media - CGT.
For teams evaluating a ready-to-use formulation, explore Kryogene Cell Freezing Media - CGT as a starting point for process-specific qualification.
What should a CAR-T freezing medium provide
A freezing medium provides a protective environment during cryopreservation. Its formulation should be considered alongside cell concentration, container format, freezing, storage, thawing, and post-thaw handling. Changing the medium alone does not establish that the complete process is suitable.
Kryogene Cell Freezing Media - CGT is chemically defined, serum-free, protein-free, and ready to use. It is designed for cell therapy applications including CAR-T cells. These formulation attributes support a more controlled preparation workflow; performance still needs to be assessed with the actual CAR-T product and its intended use.
Evaluate viability and recovery together
Post-thaw viability and viable cell recovery answer different questions. Viability describes the proportion of cells that are alive in the measured population. Recovery describes how many viable cells remain relative to the defined starting amount. A sample can have a favorable viability percentage while still losing a meaningful part of its usable cell population.
| Endpoint | Question it helps answer |
| Viability | What proportion of the measured cells remains viable? |
| Viable cell recovery | How much of the starting viable cell population is recovered? |
| CAR expression | Is the CAR-positive population retained after thawing? |
| Functional activity | Do the recovered cells perform the intended biological activity? |
A CAR-T specific comparison
The Kryogene CGT evaluation included three batches of CD19 CAR-T cells frozen at 5 × 10⁶ cells/mL and 2.5 × 10⁷ cells/mL, with a competitive medium assessed alongside Kryogene. Measurements were collected immediately after thawing and after 24 hours, allowing the assessment to extend beyond a single viability snapshot.
Figure 1. Immediate post-thaw comparison of CD19 CAR-T cells cryopreserved with Kryogene Cell Freezing Media - CGT or Competitor 1. Original panel A shows viability change, CAR expression rate change, and viable cell recovery rate at 0 h. Data: MileCell/Kryogene.
Read each endpoint on its own terms. Viability change is not absolute viability, and a change in CAR expression is not a direct measure of tumor-cell killing. When comparing media, keep assay definitions, sampling times, and the recovery denominator consistent.
Define success before comparing media
Set acceptance criteria around the cells needed for the next step, rather than selecting a medium from the most favorable individual graph. Record the pre-freeze cell count, viability, and CAR expression so that post-thaw results have an interpretable baseline.
Assess recovery beyond the moment of thawing
Cryopreservation for CAR-T cells should be evaluated at time points that reflect the intended workflow. Measurements at 0 h establish the immediate result; the 24 h assessment provides additional information about how viability, recovery, and CAR expression behave during the subsequent culture period.
Figure 2. CD19 CAR-T comparison at 24 h after thawing. Original panel B includes viable cell recovery rate, viability change, CAR expression rate change, and absolute viability for Kryogene Cell Freezing Media - CGT and Competitor 1. Data: MileCell/Kryogene.
The paired plots show endpoint- and sample-dependent differences. Read absolute viability alongside the change from baseline, and interpret recovery separately from CAR expression. The experiment supports assessment of several quality attributes together; it does not establish uniform superiority across all outcomes.
A 24 h culture assessment is not an established post-thaw administration window. Qualification should reproduce the actual handling, hold conditions, and timing expected in the intended process.
Test the intended freezing cell density
Cell concentration is part of the cryopreservation process. Evidence generated at one density should not automatically be applied to another. The CD19 CAR-T study includes 5 × 10⁶ cells/mL and 2.5 × 10⁷ cells/mL, making it possible to review batch-level trends at both tested concentrations.
Figure 3. Selected plots from original panel C at 5 × 10⁶ cells/mL. Viability and CAR expression are shown before cryopreservation and at 0 h and 24 h after thawing, with batch-specific traces retained. Data: MileCell/Kryogene.
Figure 4. Selected plots from original panel D at 2.5 × 10⁷ cells/mL. Viability and CAR expression are tracked at the same assessment points. Axis ranges differ between panels and should be read separately. Data: MileCell/Kryogene.
The traces preserve the differences between batches rather than reducing the experiment to a single headline value. The density-specific plots support evaluation under the tested conditions; they do not establish an optimal concentration for every CAR construct, donor source, or manufacturing process.
Separate CAR expression from functional potency
CAR expression is a relevant characterization endpoint, but retained expression alone does not demonstrate antigen-specific killing. Include a functional assay suited to the CAR-T product when evaluating whether cryopreservation preserves the activity needed downstream. The displayed dataset does not provide a direct cytotoxicity result.
Qualify the complete freeze–thaw workflow
A meaningful medium comparison keeps the surrounding process controlled. Use matched cell material where possible, document the starting state, and qualify the following variables together:
Cell preparation. Define the manufacturing stage, pre-freeze condition, concentration, and baseline measurements.
Freezing and storage. Document medium addition, container and fill volume, the freezing method, transfer to storage, and storage conditions.
Thawing and recovery. Control thawing, dilution or washing where applicable, post-thaw culture conditions, and time to measurement.
Analytical consistency. Use consistent counting, viability, CAR-expression, and functional-assay methods, with acceptance criteria set in advance.
FDA guidance on CAR-T development also emphasizes control of thawing and the validation of shipping, storage, and preparation procedures. See Considerations for the Development of CAR T Cell Products. A medium’s performance data should be integrated into that broader qualification strategy.
Kryogene Cell Freezing Media for CAR-T workflows
Kryogene Cell Freezing Media - CGT combines a chemically defined, serum- and protein-free formulation with ready-to-use handling and CAR-T-specific performance data. It is a relevant option for teams seeking to evaluate viability, recovery, and CAR expression together.
| Product detail | Specification |
| Product | Kryogene Cell Freezing Media - CGT |
| Bottle format | AR0008-100 • 100 mL/bottle |
| Bag format | AR0008-100B • 100 mL/bag |
| Medium storage | 2–8 °C |
| Formulation | Chemically defined; serum-free; protein-free; ready to use |
The medium storage temperature applies to the reagent, not to cryopreserved CAR-T cells. Select the supply format alongside the intended handling and transfer process.
The manufacturing quality framework includes ISO 9001. Quality-system credentials support supplier assessment, while human-derived starting material requires appropriate consent, ethical oversight, traceability, and biosafety controls for the project. Request the applicable documentation during qualification.
Frequently asked questions
Is immediate post-thaw viability enough
No. Viability should be interpreted with viable cell recovery, CAR expression, and a functional endpoint appropriate to the product. Later measurements can reveal behavior that is not captured immediately after thawing.
Which cell densities were evaluated with Kryogene CGT
Three batches of CD19 CAR-T cells were evaluated at 5 × 10⁶ cells/mL and 2.5 × 10⁷ cells/mL. These are tested experimental conditions, not universal recommendations for every CAR-T process.
Does preserved CAR expression prove preserved potency
No. CAR expression indicates receptor expression in the measured population. It does not by itself show that the cells retain antigen-specific cytotoxicity. Functional testing should be selected according to the intended biological activity.
Does serum-free mean DMSO-free
No. Serum-free, protein-free, and DMSO-free describe different formulation attributes. Confirm the composition and cryoprotectant requirements of the exact medium before use. Do not assume that the CGT formulation shares the composition of a separately named DMSO-free product.
Does the 24 h assessment define a clinical hold time
No. A post-thaw culture assessment describes the experiment performed. An allowable hold time requires stability evaluation under the actual conditions of preparation and intended use.
Choose a medium around the cells you need after thawing
Effective cryopreservation for CAR-T cells starts with clearly defined post-thaw requirements. Evaluate viability and recovery together, track CAR expression without treating it as a substitute for function, test the intended cell density, and qualify the complete handling process.
Kryogene Cell Freezing Media - CGT offers a ready-to-use, chemically defined option with comparative CD19 CAR-T data across the tested densities and time points. This provides a focused starting point for selecting a formulation to evaluate in your own workflow.
Planning a CAR-T cryopreservation study? Contact MileCell to request the CGT product datasheet and discuss your cell concentration, container format, post-thaw assays, and qualification needs.
Explore Kryogene Cell Freezing Media - CGT | Info@milecell-bio.com
Reference: FDA — Considerations for the Development of CAR T Cell Products
